# Balloon-assisted maturation versnelt AVF-maturatie zonder verlies aan 1-jaar patency

*geplaatst 2026-08-31 · Nierziekte · Renal failure · doi 10.1080/0886022X.2026.2679293 · https://hartvaat.nl/2026/12/01/balloon-assisted-maturation-versnelt-avf-maturatie-zonder-verlies-aan-1-jaar-pat/*

In een retrospectieve cohortstudie bij 129 dialysepatiënten onderzochten onderzoekers of vroege balloon-assisted maturation (BAM) van arterioveneuze fistels (AVF) de 1-jaar patency beïnvloedt. De analyse toonde geen significant verschil in patency tussen patiënten met en zonder BAM (p = 0,238), noch in de behoefte aan herinterventie (aHR 1,25; 95%-BI 0,78–2,01; p = 0,346). Deze bevindingen suggereren dat vroege BAM veilig is en overwogen kan worden bij AVF's met een langzame maturatie, zonder afbreuk te doen aan de langetermijnfunctionaliteit.

## English: Early balloon-assisted-maturation does not reduce patency of mature arteriovenous fistulae.

A single-center retrospective cohort study of 129 hemodialysis patients evaluated whether early balloon-assisted maturation (BAM) of arteriovenous fistulae (AVF) affects 1-year patency. Kaplan-Meier analysis revealed no significant difference in patency between BAM and non-BAM groups (p = 0.238), and the adjusted hazard ratio for primary intervention was 1.25 (95% CI 0.78–2.01; p = 0.346). The findings indicate that early BAM does not compromise fistula longevity and may be safely utilized to accelerate maturation in slow-developing AVFs.

## Abstract (original, from the publication)

While balloon-assisted maturation (BAM) is increasingly used to promote arteriovenous fistulae (AVF) maturation, its effects on post-maturation patency remain unclear. This study investigates the patency of BAM-matured AVF at 1 year in hemodialysis patients. This retrospective cohort study collected data from patients with AVF created between January 1st, 2017, and December 31st, 2021, with subsequent maturation and follow-up at a medical center in Taiwan. Patients were classified as BAM or non-BAM. The group receiving BAM was further stratified into early and late BAM by the median time of balloon catheter cannulation (55 days from AVF creation). Outcomes included primary intervention for mature AVF, including percutaneous transluminal angioplasty and thrombectomy, and patency at 1 year after maturation. Of the 129 eligible patients, 74 (57.36%) received BAM and 55 (42.64%) did not, with comparable baseline characteristics observed between the early- and late-BAM groups. Kaplan-Meier analysis shows comparably sustained post-maturation patency between the BAM and non-BAM (p = 0.238) and early- and late-BAM groups (p = 0.116). The risk of primary intervention was similar between the BAM and non-BAM groups (adjusted hazard ratio (aHR), 1.25; 95% confidence interval (CI), 0.78-2.01, p = 0.346) and the early-BAM and late-BAM groups (aHR, 0.64; 95% CI, 0.32-1.26, p = 0.194) at 1 year by regression analysis. The patency of mature AVF was comparable between patients with and without BAM. Early BAM did not significantly increase the risk of primary intervention at 1 year and may be considered for slow-to-mature AVF.

Auteurs: Chung-Kuan Wu, Wei-Cheng Tseng, Chia-Hsun Lin

---
Bron: Renal failure, https://doi.org/10.1080/0886022X.2026.2679293. Bijgewerkt 2026-08-25T00:51:38Z. Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.